{"name":"ANRS, Emerging Infectious Diseases","slug":"anrs-emerging-infectious-diseases","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":19,"colorKey":"cardiovascular","drugs":[{"name":"Experimental: doxycycline","genericName":"Experimental: doxycycline","slug":"experimental-doxycycline","indication":"Emerging infectious diseases (investigational indication under ANRS Phase 3 trial)","status":"phase_3"},{"name":"GenHevac-B","genericName":"GenHevac-B","slug":"genhevac-b","indication":"Chronic hepatitis B infection (therapeutic vaccination)","status":"phase_3"},{"name":"blood sampling","genericName":"blood sampling","slug":"blood-sampling","indication":"Detection and monitoring of emerging infectious diseases","status":"marketed"},{"name":"darunavir/ritonavir QD + raltegravir BID","genericName":"darunavir/ritonavir QD + raltegravir BID","slug":"darunavir-ritonavir-qd-raltegravir-bid","indication":"Treatment of HIV-1 infection","status":"phase_3"},{"name":"ARV bitherapie","genericName":"ARV bitherapie","slug":"arv-bitherapie","indication":"HIV-1 infection (investigational two-drug regimen)","status":"phase_3"},{"name":"Cabotegravir Tablets, for oral use.","genericName":"Cabotegravir Tablets, for oral use.","slug":"cabotegravir-tablets-for-oral-use","indication":"HIV-1 infection treatment (in combination antiretroviral therapy)","status":"phase_3"},{"name":"GTU-multHIV B vaccine and LIPO-5 vaccine","genericName":"GTU-multHIV B vaccine and LIPO-5 vaccine","slug":"gtu-multhiv-b-vaccine-and-lipo-5-vaccine","indication":"Prevention of HIV infection","status":"phase_2"},{"name":"GenHevac B Pasteur","genericName":"GenHevac B Pasteur","slug":"genhevac-b-pasteur","indication":"Prevention of hepatitis B infection in adults and children","status":"phase_3"},{"name":"Intensified TBM treatment","genericName":"Intensified TBM treatment","slug":"intensified-tbm-treatment","indication":"Tuberculous meningitis (TBM)","status":"phase_3"},{"name":"Lamivudine Oral Solution","genericName":"Lamivudine Oral Solution","slug":"lamivudine-oral-solution","indication":"HIV-1 infection (in combination antiretroviral therapy)","status":"marketed"},{"name":"Maraviroc (Celsentri)","genericName":"Maraviroc (Celsentri)","slug":"maraviroc-celsentri","indication":"HIV-1 infection in treatment-experienced patients with CCR5-tropic virus","status":"phase_3"},{"name":"Nucleotidic or Nucleosidic Treatment","genericName":"Nucleotidic or Nucleosidic Treatment","slug":"nucleotidic-or-nucleosidic-treatment","indication":"HIV infection (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Rifampin, isoniazid, pyrazinamide, ethambutol","genericName":"Rifampin, isoniazid, pyrazinamide, ethambutol","slug":"rifampin-isoniazid-pyrazinamide-ethambutol","indication":"Tuberculosis (drug-susceptible, pulmonary and extrapulmonary)","status":"marketed"},{"name":"Sofosbuvir and Daclatasvir for 24 weeks","genericName":"Sofosbuvir and Daclatasvir for 24 weeks","slug":"sofosbuvir-and-daclatasvir-for-24-weeks","indication":"Chronic hepatitis C virus (HCV) infection, treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Tenofovir + lamivudine + raltegravir","genericName":"Tenofovir + lamivudine + raltegravir","slug":"tenofovir-lamivudine-raltegravir","indication":"Treatment of HIV-1 infection in adults and children","status":"phase_3"},{"name":"Treatment discontinuation","genericName":"Treatment discontinuation","slug":"treatment-discontinuation","indication":"Treatment discontinuation in patients with HIV","status":"phase_3"},{"name":"WHO TBM treatment","genericName":"WHO TBM treatment","slug":"who-tbm-treatment","indication":"Tuberculous meningitis (TBM)","status":"phase_3"},{"name":"atazanavir boosted with ritonavir","genericName":"atazanavir boosted with ritonavir","slug":"atazanavir-boosted-with-ritonavir","indication":"Treatment of HIV-1 infection in adults and children","status":"phase_3"},{"name":"darunavir; ritonavir; emtricitabine/tenofovir","genericName":"darunavir; ritonavir; emtricitabine/tenofovir","slug":"darunavir-ritonavir-emtricitabine-tenofovir","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"immunology","drugs":[{"name":"A peripheral blood sample","genericName":"A peripheral blood sample","slug":"a-peripheral-blood-sample","indication":"Other","status":"phase_1"},{"name":"ABC-3TC-EFV once a day","genericName":"ABC-3TC-EFV once a day","slug":"abc-3tc-efv-once-a-day","indication":"Other","status":"phase_2"},{"name":"Reinforced preventive ARV therapy","genericName":"Reinforced preventive ARV therapy","slug":"reinforced-preventive-arv-therapy","indication":"Other","status":"marketed"},{"name":"Amniotic fluid sampling","genericName":"Amniotic fluid sampling","slug":"amniotic-fluid-sampling","indication":"Fetal health assessment during pregnancy","status":"phase_2"},{"name":"BBIBP-CorV","genericName":"BBIBP-CorV","slug":"bbibp-corv","indication":"Other","status":"phase_2"},{"name":"Bexsero® vaccine","genericName":"Bexsero® vaccine","slug":"bexsero-vaccine","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in infants, children, adolescents, and adults","status":"phase_3"},{"name":"Boceprevir, Peg-interferon alfa 2b and Ribavirin","genericName":"Boceprevir, Peg-interferon alfa 2b and Ribavirin","slug":"boceprevir-peg-interferon-alfa-2b-and-ribavirin","indication":"Other","status":"phase_2"},{"name":"Breast milk sampling","genericName":"Breast milk sampling","slug":"breast-milk-sampling","indication":"Monitoring of breast milk for various substances","status":"phase_2"},{"name":"Cormirnaty","genericName":"Cormirnaty","slug":"cormirnaty","indication":"Other","status":"phase_1"},{"name":"Ervebo","genericName":"Ervebo","slug":"ervebo","indication":"Other","status":"marketed"},{"name":"Fumarate, Tenofovir Disoproxil","genericName":"Fumarate, Tenofovir Disoproxil","slug":"fumarate-tenofovir-disoproxil","indication":"Other","status":"marketed"},{"name":"Inmazeb","genericName":"Inmazeb","slug":"inmazeb","indication":"Ebola virus disease","status":"marketed"},{"name":"Romidepsin cycle 2","genericName":"Romidepsin cycle 2","slug":"romidepsin-cycle-2","indication":"Other","status":"phase_1"},{"name":"Solo 0.3 group","genericName":"Solo 0.3 group","slug":"solo-0-3-group","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fluoxétine and Budésonide","genericName":"Fluoxétine and Budésonide","slug":"fluox-tine-and-bud-sonide","indication":"Major depressive disorder","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Antiretroviral therapy","genericName":"Antiretroviral therapy","slug":"antiretroviral-therapy","indication":"HIV-1 infection (treatment and prevention)","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Pegylated Interferon alpha-2a","genericName":"Pegylated Interferon alpha-2a","slug":"pegylated-interferon-alpha-2a","indication":"Chronic hepatitis C","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Veklury","genericName":"Veklury","slug":"veklury","indication":"Disease caused by Severe acute respiratory syndrome coronavirus 2","status":"marketed"}]}],"pipeline":[{"name":"Fluoxétine and Budésonide","genericName":"Fluoxétine and Budésonide","slug":"fluox-tine-and-bud-sonide","phase":"phase_2","mechanism":"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and budesonide is a corticosteroid.","indications":["Major depressive disorder","Asthma"],"catalyst":""},{"name":"A peripheral blood sample","genericName":"A peripheral blood sample","slug":"a-peripheral-blood-sample","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ABC-3TC-EFV once a day","genericName":"ABC-3TC-EFV once a day","slug":"abc-3tc-efv-once-a-day","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Experimental: doxycycline","genericName":"Experimental: doxycycline","slug":"experimental-doxycycline","phase":"phase_3","mechanism":"Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation.","indications":["Emerging infectious diseases (investigational indication under ANRS Phase 3 trial)"],"catalyst":""},{"name":"GenHevac-B","genericName":"GenHevac-B","slug":"genhevac-b","phase":"phase_3","mechanism":"GenHevac-B is a therapeutic hepatitis B vaccine designed to boost immune response in chronically infected patients by presenting hepatitis B surface antigen (HBsAg) to stimulate T-cell and B-cell immunity.","indications":["Chronic hepatitis B infection (therapeutic vaccination)"],"catalyst":""},{"name":"Reinforced preventive ARV therapy","genericName":"Reinforced preventive ARV therapy","slug":"reinforced-preventive-arv-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"blood sampling","genericName":"blood sampling","slug":"blood-sampling","phase":"marketed","mechanism":"Blood sampling is a diagnostic procedure that collects blood specimens for laboratory analysis to detect pathogens, assess immune response, or monitor disease markers.","indications":["Detection and monitoring of emerging infectious diseases","Pathogen surveillance and epidemiological tracking"],"catalyst":""},{"name":"darunavir/ritonavir QD + raltegravir BID","genericName":"darunavir/ritonavir QD + raltegravir BID","slug":"darunavir-ritonavir-qd-raltegravir-bid","phase":"phase_3","mechanism":"Darunavir/ritonavir QD is a protease inhibitor that blocks HIV replication, while raltegravir BID is an integrase strand transfer inhibitor that also blocks HIV replication.","indications":["Treatment of HIV-1 infection"],"catalyst":""},{"name":"ARV bitherapie","genericName":"ARV bitherapie","slug":"arv-bitherapie","phase":"phase_3","mechanism":"ARV bitherapie is a two-drug antiretroviral combination regimen designed to suppress HIV replication by targeting viral reverse transcriptase and/or protease enzymes.","indications":["HIV-1 infection (investigational two-drug regimen)"],"catalyst":""},{"name":"Amniotic fluid sampling","genericName":"Amniotic fluid sampling","slug":"amniotic-fluid-sampling","phase":"phase_2","mechanism":"Amniotic fluid sampling is a diagnostic procedure that involves collecting a sample of amniotic fluid for analysis.","indications":["Fetal health assessment during pregnancy"],"catalyst":""},{"name":"Antiretroviral therapy","genericName":"Antiretroviral therapy","slug":"antiretroviral-therapy","phase":"marketed","mechanism":"Antiretroviral therapy (ART) suppresses HIV replication by blocking viral enzymes (reverse transcriptase, integrase, protease) and/or preventing viral entry into CD4+ T cells.","indications":["HIV-1 infection (treatment and prevention)","AIDS (acquired immunodeficiency syndrome)"],"catalyst":""},{"name":"BBIBP-CorV","genericName":"BBIBP-CorV","slug":"bbibp-corv","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Bexsero® vaccine","genericName":"Bexsero® vaccine","slug":"bexsero-vaccine","phase":"phase_3","mechanism":"Bexsero is a recombinant meningococcal B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in infants, children, adolescents, and adults"],"catalyst":""},{"name":"Boceprevir, Peg-interferon alfa 2b and Ribavirin","genericName":"Boceprevir, Peg-interferon alfa 2b and Ribavirin","slug":"boceprevir-peg-interferon-alfa-2b-and-ribavirin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Breast milk sampling","genericName":"Breast milk sampling","slug":"breast-milk-sampling","phase":"phase_2","mechanism":"This drug is used to monitor the levels of various substances in breast milk.","indications":["Monitoring of breast milk for various substances"],"catalyst":""},{"name":"Cabotegravir Tablets, for oral use.","genericName":"Cabotegravir Tablets, for oral use.","slug":"cabotegravir-tablets-for-oral-use","phase":"phase_3","mechanism":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.","indications":["HIV-1 infection treatment (in combination antiretroviral therapy)","HIV-1 pre-exposure prophylaxis (PrEP)"],"catalyst":""},{"name":"Cormirnaty","genericName":"Cormirnaty","slug":"cormirnaty","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ervebo","genericName":"Ervebo","slug":"ervebo","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Fumarate, Tenofovir Disoproxil","genericName":"Fumarate, Tenofovir Disoproxil","slug":"fumarate-tenofovir-disoproxil","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GTU-multHIV B vaccine and LIPO-5 vaccine","genericName":"GTU-multHIV B vaccine and LIPO-5 vaccine","slug":"gtu-multhiv-b-vaccine-and-lipo-5-vaccine","phase":"phase_2","mechanism":"The GTU-multHIV B vaccine and LIPO-5 vaccine target multiple HIV epitopes to stimulate both humoral and cellular immune responses.","indications":["Prevention of HIV infection"],"catalyst":""},{"name":"GenHevac B Pasteur","genericName":"GenHevac B Pasteur","slug":"genhevac-b-pasteur","phase":"phase_3","mechanism":"GenHevac B Pasteur is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen.","indications":["Prevention of hepatitis B infection in adults and children"],"catalyst":""},{"name":"Inmazeb","genericName":"Inmazeb","slug":"inmazeb","phase":"marketed","mechanism":"Low affinity immunoglobulin gamma Fc region receptor III-A, Envelope glycoprotein","indications":["Ebola virus disease"],"catalyst":""},{"name":"Intensified TBM treatment","genericName":"Intensified TBM treatment","slug":"intensified-tbm-treatment","phase":"phase_3","mechanism":"Intensified TBM treatment uses higher doses and/or more frequent administration of anti-tuberculous drugs to improve penetration into the central nervous system and enhance bacterial killing in tuberculous meningitis.","indications":["Tuberculous meningitis (TBM)"],"catalyst":""},{"name":"Lamivudine Oral Solution","genericName":"Lamivudine Oral Solution","slug":"lamivudine-oral-solution","phase":"marketed","mechanism":"Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing viral replication by inhibiting the conversion of viral RNA to DNA.","indications":["HIV-1 infection (in combination antiretroviral therapy)","Chronic hepatitis B infection"],"catalyst":""},{"name":"Maraviroc (Celsentri)","genericName":"Maraviroc (Celsentri)","slug":"maraviroc-celsentri","phase":"phase_3","mechanism":"Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells.","indications":["HIV-1 infection in treatment-experienced patients with CCR5-tropic virus","HIV-1 infection in treatment-naïve patients with CCR5-tropic virus"],"catalyst":""},{"name":"Nucleotidic or Nucleosidic Treatment","genericName":"Nucleotidic or Nucleosidic Treatment","slug":"nucleotidic-or-nucleosidic-treatment","phase":"phase_3","mechanism":"Nucleotidic or nucleosidic compounds inhibit viral reverse transcriptase and/or other viral enzymes to suppress replication of retroviruses or other nucleic acid-dependent pathogens.","indications":["HIV infection (as part of combination antiretroviral therapy)","Hepatitis B virus infection"],"catalyst":""},{"name":"Pegylated Interferon alpha-2a","genericName":"Pegylated Interferon alpha-2a","slug":"pegylated-interferon-alpha-2a","phase":"marketed","mechanism":"Pegylated interferon alpha-2a activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and antiproliferative activity.","indications":["Chronic hepatitis C","Chronic hepatitis B","Certain malignancies (melanoma, renal cell carcinoma)"],"catalyst":""},{"name":"Rifampin, isoniazid, pyrazinamide, ethambutol","genericName":"Rifampin, isoniazid, pyrazinamide, ethambutol","slug":"rifampin-isoniazid-pyrazinamide-ethambutol","phase":"marketed","mechanism":"This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production, killing Mycobacterium tuberculosis.","indications":["Tuberculosis (drug-susceptible, pulmonary and extrapulmonary)","Tuberculosis treatment in treatment-naïve patients"],"catalyst":""},{"name":"Romidepsin cycle 2","genericName":"Romidepsin cycle 2","slug":"romidepsin-cycle-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sofosbuvir and Daclatasvir for 24 weeks","genericName":"Sofosbuvir and Daclatasvir for 24 weeks","slug":"sofosbuvir-and-daclatasvir-for-24-weeks","phase":"marketed","mechanism":"Sofosbuvir inhibits hepatitis C virus (HCV) NS5B RNA polymerase while daclatasvir inhibits NS5A protein, together blocking viral replication.","indications":["Chronic hepatitis C virus (HCV) infection, treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Solo 0.3 group","genericName":"Solo 0.3 group","slug":"solo-0-3-group","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Tenofovir + lamivudine + raltegravir","genericName":"Tenofovir + lamivudine + raltegravir","slug":"tenofovir-lamivudine-raltegravir","phase":"phase_3","mechanism":"Tenofovir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV replication by inhibiting viral DNA synthesis. Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV replication by inhibiting viral integration into the host genome.","indications":["Treatment of HIV-1 infection in adults and children","Prevention of mother-to-child transmission of HIV"],"catalyst":""},{"name":"Treatment discontinuation","genericName":"Treatment discontinuation","slug":"treatment-discontinuation","phase":"phase_3","mechanism":"Treatment discontinuation is a process where a patient stops taking a medication.","indications":["Treatment discontinuation in patients with HIV"],"catalyst":""},{"name":"Veklury","genericName":"Veklury","slug":"veklury","phase":"marketed","mechanism":"NS5, Replicase polyprotein 1ab","indications":["Disease caused by Severe acute respiratory syndrome coronavirus 2"],"catalyst":""},{"name":"WHO TBM treatment","genericName":"WHO TBM treatment","slug":"who-tbm-treatment","phase":"phase_3","mechanism":"WHO TBM treatment is a standardized therapeutic regimen combining antimicrobial agents optimized for tuberculous meningitis, targeting Mycobacterium tuberculosis in the central nervous system.","indications":["Tuberculous meningitis (TBM)"],"catalyst":""},{"name":"atazanavir boosted with ritonavir","genericName":"atazanavir boosted with ritonavir","slug":"atazanavir-boosted-with-ritonavir","phase":"phase_3","mechanism":"Atazanavir is a protease inhibitor that blocks the protease enzyme in HIV, preventing the virus from replicating.","indications":["Treatment of HIV-1 infection in adults and children","Prevention of mother-to-child transmission of HIV"],"catalyst":""},{"name":"darunavir; ritonavir; emtricitabine/tenofovir","genericName":"darunavir; ritonavir; emtricitabine/tenofovir","slug":"darunavir-ritonavir-emtricitabine-tenofovir","phase":"phase_3","mechanism":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","HIV-1 infection in resource-limited settings (ANRS focus)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPdUltY3RCc0JTZk40V3dFX0xUZmNFLTU5QUNpMlR0aGZLdFoxdzJ2M1dkMHBmZFQwVGZYNE1aSnhoLURkaDNuWFV6RnFrNFhCb3d5c2NWTzZZU0NBWHlJRk5nRTRoRHM1N3QzMDI0Y3c4eXRTV29vTWdDR3NzSGYxemxBdXNwOUdTS1k0SWVjeld1OEt0OElCMlBsblZCaldvWmVpaUZXekxicGp6aEg5VA?oc=5","date":"2026-03-10","type":"pipeline","source":"Laodong.vn","summary":"Professor who won the 2008 Nobel Prize in Medicine attends conference at Hanoi Medical University - Laodong.vn","headline":"Professor who won the 2008 Nobel Prize in Medicine attends conference at Hanoi Medical University","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSHhtNjQ0TEs2SEwtdXRhRF9renZERUVXM2F5UThjZ25CY09tbEJTdFo0OF9oS1JwV21iTk1SRkdLV1FUOWVvdVFBNXNvd3RRb2dZUEVPUUsxcGEzOHU4SHVFWThpSjMxd2dpTG1uYWtQcDJEWjJpTGxuTkxDZXVWclFUVGl0cEhIMDcyRUdWUkRyeThUYUk3MDdDUGtIZmZVcFN6Z1J2eTA?oc=5","date":"2026-02-25","type":"pipeline","source":"Devex","summary":"When the next global health crisis strikes, will we be ready in 100 days? - Devex","headline":"When the next global health crisis strikes, will we be ready in 100 days?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNeUlmZVBIU2FOQ0EwWWh0eFZISHlxRHNheHlsSnlIZ21lQVhkUnk5SXVrYXRlSjV6VjJPdE81NjYzeE5SLTRTSVZiZlhtNy1SYW9FaTU1NHd0dE9kUm50VjRhWXRyb0Njc29MYV80UzFBenZmazdWek90MDBydWZrU0NIWmtLMzg1MTVTN2dQZ3lrTmZyWDRzcnBRWGxxUWJidV9mZWdTUDBjYmdmRU5JOHRXYXNZZw?oc=5","date":"2026-02-18","type":"pipeline","source":"EU Reporter","summary":"Europe invests €240 million in ten-year pandemic preparedness research - EU Reporter","headline":"Europe invests €240 million in ten-year pandemic preparedness research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5HYUk0c0tmckpvNkFqdjVSaFpqMTM0eVhHNHRHVFlIMGRFWEF0bmFHTmdOemxDR1RYZENLTEdpaXZxOHk0dVJGSFBpTjRaRjAzeUFDdkstOFNWRUxIanc3d091OFY1Rkh6aEZRRg?oc=5","date":"2026-02-05","type":"pipeline","source":"ANRS Maladies infectieuses émergentes","summary":"Innovation Committee: guiding and advising innovative project leaders - ANRS Maladies infectieuses émergentes","headline":"Innovation Committee: guiding and advising innovative project leaders - ANRS Maladies infectieuses émergentes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFB3eWJQZTRkcG9mMU9SdmxaVTNDNTNNY3dOV2p6NElibmI5WmI5MXFLTnNpaDV4Um5yaVJzR04wQjFHeEtibXlJLUV0Z1BWcWZTS2JaNVU1S3RwbFk?oc=5","date":"2026-01-30","type":"pipeline","source":"ANRS Maladies infectieuses émergentes","summary":"January 30th – World Neglected Tropical Diseases Day - ANRS Maladies infectieuses émergentes","headline":"January 30th – World Neglected Tropical Diseases Day - ANRS Maladies infectieuses émergentes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9CVDVJV2tDY29fUW5XWE12OHdKUEp2TGJxajVuU0Y1VF9iMF9admtHS3lLRUhOaktLczdyZnFhU3FxNWRlYllrbXR3d1lseGoxRVVOSkNPWG5JQWhTOGFPOXplS18?oc=5","date":"2026-01-27","type":"pipeline","source":"ANRS Maladies infectieuses émergentes","summary":"100 Days Mission - Fifth Implementation Report Launch - ANRS Maladies infectieuses émergentes","headline":"100 Days Mission - Fifth Implementation Report Launch - ANRS Maladies infectieuses émergentes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5PSlZzX2tweFI2UEJnSzAybF9lQ2RyR3VfM2E1RW84UjM1QlpPMnlFcEZsb0JNRl8tX2psLVFjQ2lWQ1FWX1c4dDV1UzQ3bXBRdERoWVF1Wm5ENS01blBHZDhLN3RFa01jQnc?oc=5","date":"2025-11-26","type":"pipeline","source":"ANRS Maladies infectieuses émergentes","summary":"ANRS MIE Scientific Days 2026 - ANRS Maladies infectieuses émergentes","headline":"ANRS MIE Scientific Days 2026 - ANRS Maladies infectieuses émergentes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBxcEVEWW9Ud2JTczRYbjlSS1lYRTBxSTNENE1yU1NzdG82X3hRWjhDMGxVaUE5d2FYY3BRdmFHemIyZnd5d2pHVEpSdmdGQjVNVG44Q2tXd3Z4bFAyeHM0MDVuWVNwRmJNYXFObVIwdV9XUGdMMTRGOFoyVno?oc=5","date":"2025-09-30","type":"pipeline","source":"Université Paris Cité","summary":"HIV: Early Treatment, One Key to Remission - Université Paris Cité","headline":"HIV: Early Treatment, One Key to Remission - Université Paris Cité","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE95UXNSVlNLUUV4RVZfdk1pOXU2cUk3dlZFZXNiNnd5bFZqRlA2WTJybmFvWWMxaXRBSExXVGFrOXNrQXhVeFpadklrNWRReXZBelVjTFBjTTIwZU1rX2pjb0NNOA?oc=5","date":"2025-09-02","type":"trial","source":"ANRS Maladies infectieuses émergentes","summary":"Press Release – MUCOBOOST Clinical Trial - ANRS Maladies infectieuses émergentes","headline":"Press Release – MUCOBOOST Clinical Trial - ANRS Maladies infectieuses émergentes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPM3pDY0JoOFlBYk9NWjVsZ1BWbml6b1hhamJqQmpnbzhvNHh3YUhaVjdzMDJuZ3NmOFVKbkdQLVlSQ1BFdzFiSDJfa1ZrVUdhNnZaVVF1VDRROVpEWmNKcXA5cjJ1QXQzczR3Rk5Tc3d6OUxCYzJVdDRyOVhrMXFBTjU3Rmx1U1ZOYUxJOFA5M0I?oc=5","date":"2025-04-08","type":"pipeline","source":"Medscape","summary":"HIV Crisis Looms Amid Global Aid Cuts - Medscape","headline":"HIV Crisis Looms Amid Global Aid Cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQaTZoQjIwV3pvaTRtV2Ffc2NFeGNxUE1TYTlxbU9MRHR1b3BEWE56bTh1eGMxaHp6dTBfMklNdTUzYVZ1S3ZaMm9iZlItenM1LWd4UFVkMXVwU3ZTUDJ2WkF4eHc0aGpHNXhubmRiYk84Q1B1TFNXMXJ1aHdlWmtmQTVsRWxyOGNUSGdrNzNSMUxlOWR0?oc=5","date":"2024-01-16","type":"pipeline","source":"Institut Pasteur","summary":"HIV: early treatment, one key to remission | - Institut Pasteur","headline":"HIV: early treatment, one key to remission |","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQSUxGcldKaDk2dG8xZEQxSzVUTXhscnU2NGdhWVpVNFlsNDlQTm5YMEVxMEp5SHpwVWJMT0pPbV9vTjN4VzZzc05TbkxlZGlpNmQtc0x4NnhhbmxWVHhjUmxLOWZDZnpLOThTMTNQVEZ4Q0NOUnQ0UC1MeDYydGVXVlpsX3dQbnRVOEN6QzlVX3AtNnBTblduU0lSaDJWZjdDOXRVREVURG51MDhNa2NOVXF1dVBITDViSEtKdmFxQkRCNEhlaDBQVHUwdEszSHloV29pdkZmU0xwM2Y0OUd0MllPV2JZNWs?oc=5","date":"2022-10-24","type":"pipeline","source":"eatg.org","summary":"Efficacy of a meningococcal B vaccine and a preventive antibiotic in reducing the risk of sexually transmitted infections - eatg.org","headline":"Efficacy of a meningococcal B vaccine and a preventive antibiotic in reducing the risk of sexually transmitted infection","sentiment":"neutral"}],"patents":[],"drugCount":37,"phaseCounts":{"phase_2":7,"phase_1":4,"phase_3":15,"marketed":11},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}